Scholars@Duke
Elizabeth Mendes

Selected Publications

Abstract 1092: RUNX2 inhibition alters PAX3::FOXO1 driven fusion-positive rhabdomyosarcoma cell state and growth

Conference Cancer Research · March 22, 2024 AbstractInvestigation: Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive pediatric cancer of skeletal muscle lineage. While the incidence of RMS is ~4.5 patients per million individuals aged &lt ... Full text Cite

Abstract 5960: Targeting CDK8: A translatable therapeutic approach for fusion-positive aRMS

Conference Cancer Research · March 22, 2024 AbstractAlveolar rhabdomyosarcoma (aRMS), characterized by poor overall survival and limited advancements in therapy over the past four decades, poses a great challenge in childhood cancer treatment. More th ... Full text Cite

2023 ASPHO Conference Paper and Poster Index

Journal Article Pediatric Blood & Cancer · June 2023 Full text Cite

Data from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses

Other · April 4, 2023 <div>Abstract<p>The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype ... Full text Cite

Data from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses

Other · April 4, 2023 <div>Abstract<p>The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype ... Full text Cite

Abstract 3534: Interrogating the immune microenvironment of a novel mouse model of fusion positive rhabdomyosarcoma

Conference Cancer Research · April 4, 2023 AbstractImmunotherapies have been largely ineffective for pediatric soft tissue sarcomas, in particular for fusion-positive rhabdomyosarcoma (FP-RMS), characterized by the PAX-FOXO1 gene fusion. We are hampe ... Full text Cite

APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.

Journal Article Cancer Immunol Res · January 2022 The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype of breast cancer and are associated ... Full text Link to item Cite